Answers are grounded in this paper and cite their sources.
This year’s thematic is the sixteenth of the Immunological Investigations’ thematic issues, and is entitled, “Comparative and evolutionary aspects of tumor immunity”. This issue was suggested by the editorial board last year. Since state of the art tumor therapeutic regimes increasingly involve stimulation of tumor immunity by blocking various areas of immune downregulation, the evolution of immunity to tumors is of renewed interest. Insight into the elegance of the immune system with its specificity, scope and ability to distinguish between self and non-self can be obtained by looking at the more evolutionarily primitive species. Thus, in this 16th thematic issue of Immunological Investigations, we focused on evolutionary models of tumor immunity where innate or adaptive immune system components play a role. As suggested by the title, this topic is intentionally broad in scope. This is a collection of articles on tumor immunology with “The expression of ILT4 in myeloid dendritic cells in patients with hepatocellular carcinoma” by Lili Wang, Jing Fan, Wei Ye, Jianbo Han, Yufeng Zhang, Liang Zhao, Jie Duan, Dandan Yin, and Yongxiang Yi (Wang et al., 2019); “TNF may negatively regulate phagocytosis of Devil Facial Tumour disease cells by activated macrophages” by Korner, Heinrich, Li, Xinying; Darby, Jocelyn; Lyons, Alan; Woods, Gregory (Li et al., 2019b); “Devil facial tumors: towards a vaccine” by Owen, R and Siddle, H.V. (Owen and Siddle, 2019); “Evolutionary underpinnings of innate-like T cell interactions with cancer” by Robert and Banach (Banach and Robert, 2019); “Cloning and analysis of the multiple transcriptomes of serine protease homologs in crayfish (Procambarus clarkii)” by Zeng (Zeng, 2019), Sodium Butyrate as a Histone Deacetylase Inhibitor Affects Toll-Like Receptor 4 Expression in Colorectal Cancer Cell Lines. (Kazemi, 2019) and an Introduction to “Comparative and evolutionary aspects of tumor immunity” by Jacques Robert (Robert, 2019). Thus far in 2019, several Immunological Investigation articles have focused on stimulation of tumor immunity including “PD-1 haplotype combinations and susceptibility of patients to squamous cell carcinomas of head and neck” (Fathi et al., 2019), “Antigenpresenting cell characteristics of human γδ T lymphocytes in chronic myeloid leukemia” (Sawaisorn et al., 2019), “Enhanced anti-leukemic effects through induction of immunomodulating microenvironment by blocking CXCR4 and PD-L1 in an AML mouse model” (Hwang et al., 2019), “Effects of Soluble Tumor Necrosis Factor (TNF) on AntibodyDependent Cellular Cytotoxicity of Therapeutic anti-TNF-α Antibody” (Hirosaki 2019), Prognostic values of CD38CD101PD1CD8 T cells in pancreatic cancer” (Zhang et al., 2019), “Poly lactic-co-glycolic acid nanoparticles containing human gastric tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy” (Kohnepoushi et al., 2019). In the last 3 years, many articles have focused on tumor immunity, including these from the 2016 thematic issue Contributions of Tregs with disease (Wang et al., 2016), “Minireview: regulatory T cells and ovarian cancer” (Singh et al., 2016), “Tumor-associated glycans and Tregs in immunogenicity of an autologous cell-based vaccine” (MonzaviKarbassi and Kieber-Emmons, 2016), “Co-stimulate or co-inhibit regulatory T cells, which IMMUNOLOGICAL INVESTIGATIONS 2019, VOL. 48, NO. 7, 673–679 https://doi.org/10.1080/08820139.2019.1645985
No takes yet. Share an insight, caveat, or question.
Kate Rittenhouse‐Olson (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: